SCHEMBL1408246

SCHEMBL1408246

CON(C)C(=O)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 6/20 0.54
NR1H3 Q13133 6/20 0.54
CYP19A1 P11511 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 2/20 0.38
WNK1 Q9H4A3 1/20 0.38
POLB P06746 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GUCY1B2 O75343 1/20 0.37
CYP1A2 P05177 1/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
CYP2D6 P10635 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD1 P21728 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407552 0.84 NR1H2 (0.58) NR1H2NR1H3CYP19A1MAPTHTT
SCHEMBL1407101 0.83 NR1H3 (0.62) NR1H2NR1H3CYP19A1MAPTALDH1A1
SCHEMBL1407373 0.82 NR1H3 (0.61) NR1H2NR1H3CYP19A1L3MBTL1ALDH1A1
SCHEMBL27730716 0.81 NR1H2 (0.59) NR1H2NR1H3CYP19A1L3MBTL1ALDH1A1
SCHEMBL1408242 0.80 NR1H2 (0.53) NR1H2NR1H3CYP19A1MAPTHTT
SCHEMBL1407853 0.78 NR1H3 (0.62) NR1H2NR1H3CYP19A1MAPTL3MBTL1
SCHEMBL28770633 0.75 NR1H2 (0.58) NR1H2NR1H3CYP19A1MAPTHTT
SCHEMBL1408119 0.75 NR1H2 (0.57) NR1H2NR1H3
SCHEMBL1407734 0.74 NR1H3 (0.66) NR1H2NR1H3CYP19A1HTTALDH1A1
SCHEMBL3862094 0.73 NR1H3 (0.69) NR1H2NR1H3L3MBTL1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885CYP19A1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.